Marshall Wace
TCON

Marshall Wace’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Marshall Wace’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,818
Closed -$366K – 3529
2021
Q2 		$366K Sell
2,818
-4,250
-60% -$588K ﹤0.01% 2259
2021
Q1 		$1.16M Buy
+7,068
New +$1.36M 0.01% 1585

Other funds holding TCON

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace's TCON Position: Q3 2021 in Review

Marshall Wace sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q3 2021, closing a stake of 2,818 shares — an estimated $366K sold.

Marshall Wace first reported a position in TCON in Q1 2021 and held it in 2 quarters. The position peaked at $1.16M in Q1 2021. 44 funds tracked by Wall St. Rank hold TCON as of Q3 2021.

  • Marshall Wace reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace sold 2,818 TRACON Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $366K.
  • Marshall Wace first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Marshall Wace's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $1.16M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.